依达拉奉治疗基底节区脑出血患者的临床疗效观察  

Edaravone's Clinical Efficacy for Cerebral Hemorrhage of Basal Ganglia

作　　者：陈狄洪[1] 潘军利[1] 

机构地区：[1]中山大学附属中山医院神经内科,中山528400

出　　处：《中国医药导刊》2010年第5期816-817,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察依达拉奉治疗基底节区脑出血急性期的临床疗效。方法:分析我院2008～2009年112例基底节区脑出血患者的临床资料,对比应用依达拉奉1周组、10天以上组及未用组发病初及2周时的神经功能缺损程度.分析不同组别的差异,观察药物的治疗效果。结果:应用依达拉奉治疗1周组ESS由治疗前的(38.58±15.32)分上升到治疗后的(53.56±16.14)分;应用依达拉奉10天以上组ESS由治疗前的(43.10±14.26)分上升到治疗后的(63.80±14.38)分;未应用组ESS由治疗前的(41.30±14.46)分改变为治疗后的(42.70±18.87)分;三组治疗后比较,前两组无明显统计学差异,应用组及未应用组的差异有统计学意义(P<0.05)。应用组无明显不良反应。结论:依达拉奉能改善脑出血患者急性期的神经功能缺失症状,且应用1周同更长时间疗效相近。Objective： To analyse the clinical efficacy of Edaravone for patients with cerebral hemorrhage of basal ganglia.Methods： 112 cases＇ clinical data of cerebral hemorrhage of basal ganglia in Zhongshan Hospital 2008-2009 were reviewed retrospectively. Their neurologic impairment was analyzed after 2 weeks by assessing the indicators. And the effect of the drug was observed too. Results： The ESS of Edaravone treatment group 1 week rise up from （38.58±15.32） to （53.56±16.14）; The ESS of application of edaravone more than 10 days rise up from （43.10±14.26） to （63.80±14.38）; The ESS of non-application group rise up from （41.30±14.46） to （42.70±18.87）.There is no significant difference between application groups, but statistically significant between application group and non-application group （P 〈0. 05）. Adverse reactions were not observed in application group. Conclusions：The neurological function can be improved incompletely by Edaravone for patients with acute cerebral hemorrhage of basal ganglia, and there is no difference between application groups of different medication time.

关 键 词：脑出血 依达拉奉 临床观察 

分 类 号：R743.34[医药卫生—神经病学与精神病学]